NEVVI Medicare utilization intelligence
or

← back

Provider profile

POLE, CAMERON M.D.

Ophthalmology · NPI 1386090074 · LOS ANGELES, CA

1
Groups
30
Codes · 2024
50,984
Disclosed services

POLE, CAMERON is a Ophthalmology in LOS ANGELES, CA, a member of 1 medical group, who billed 30 distinct codes to Medicare Part B in 2024.

Groups: VITREO-RETINAL MEDICAL GROUP, INC. (YUBA CITY, CA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒

Provider overview · all codes · CY2024

50,984
disclosed services
30
codes billed to Medicare Part B
Prior year · CY2023 47,174 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J2777 Injection, faricimab-svoa, 0.1 mg
92134 Imaging of retina
J0177 Injection, aflibercept hd, 1 mg
Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
67028 Injection of drug into eye
J2781 Injection, pegcetacoplan, intravitreal, 1 mg
J0178 Injection, aflibercept, 1 mg
92012 Established patient problem focused exam of visual system
92014 Established patient complete exam of visual system
Q5124 Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
92235 Exam of retinal blood vessels using a special camera after injection of a dye
J7312 Injection, dexamethasone, intravitreal implant, 0.1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
92004 New patient complete exam of visual system
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
92250 Photography of the retina
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg
J3490 Unclassified drugs
76512 2d ultrasound scan of eye tissue and structures
67228 Destruction of leaking blood vessels of retina using laser
67041 Removal of membrane of retina
67036 Removal of eye fluid (vitreous) between lens and retina
67145 Photocoagulation treatment to prevent detachment of retina
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
92201 Extended exam of the back part of the eye with retinal drawing
67515 Injection of drug or substance into membrane covering eyeball
67108 Repair of detached retina with drainage and removal of eye fluid between lens and retina
J7999 Compounded drug, not otherwise classified
67042 Removal of membrane of retina with removal of internal limiting membrane of retina

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.